2D and 3D QSAR study on amino nicotinic acid and isonicotinic acid derivatives as potential inhibitors of dihydroorotate dehydrogenase (DHODH)

Medicinal Chemistry Research

Volumn 21, Issue 10, 2012, Pages 3021-3034

  Vyas, Vivek K ^a   Ghate, Manjunath ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

2D QSAR; Amino nicotinic acid and isonicotinic acid derivatives; CoMFA; Dihydroorotate dehydrogenase (DHODH); hDHODH inhibitors

Indexed keywords

AMINO NICOTINIC ACID; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; ISONICOTINIC ACID; NICOTINIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84866343619     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9837-4     Document Type: Article

References (23)

1. Balaban AT (1982) Highly discriminating distance-based topological index. Chem Phys Lett 89:399-404
2. Baumann P, Mandl WS, Volkl A, Adam C, Bumeder I, Oduncu F, Schmidmaier RA (2009) Perspective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(R) gel as adhesion prophylaxis after major abdominal surgery versus non-treated group. Mol Cancer Ther 8:366-375
3. Bjornberg O, Rowland P, Larsen S, Jensen KF (1997) Active site of dihydroorotate dehydrogenase A from Lactococcus lactis investigated by chemical modification and mutagenesis. Biochemistry 36:16197-16205
4. Bjornberg O, Gruner AC, Roepstorff P, Jensen KF (1999) The activity of Escherichia coli dihydroorotate dehydrogenase is dependent on a conserved loop identified by sequence homology, mutagenesis, and limited proteolysis. Biochemistry 38:2899-2908
5. Castro PLJC, Erra SM, Lozoya TME, Navarro RE (2010) Amino nicotinic acid and isonicotinic acid derivative as DHODH inhibitor. US patent US20100074898
6. Chen SF, Ruben RL, Dexter DL (1986) Mechanism of action of the novel anticancer agent 6-fluoro-2-(20-fluoro-1,10-biphenyl-4-yl)- 3-methyl-4- quinolinecarboxylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res 46:5014-5019
7. Clark M, Cramer RD, OpdenboschNV(1989) Validation of the general purpose Tripos 5.2 forcefield. J Comput Chem 10:982-1012
8. Croux C, Joossens K (2005) Influence of observations on the misclassification probability in quadratic discriminant analysis. J Multivar Anal 96:348-403
9. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, Kirschbaum BJ (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93:198-208
10. Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 36:3219-3228
11. Herrmann ML, Schleyerbach R, Kirschbaum BJ (2004) Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 47:273-289
12. Huberty CJ (1984) Issues in the use and interpretation of discriminant analysis. Psychol Bull 95:156-171
13. Jones M (1980) Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. Annu Rev Biochem 49:253-279
14. Kubyani H (1994) Variable selection in QSAR studies. I. An evolutionary algorithm. Quant Struct Act Relat 13:285-294
15. Mascia L, Turchi G, Bemi V, Ipata PL (2000) Uracil salvage pathway in PC12 cells. Biochem Biophys Acta 1524:45-50
16. Merrill JE, Hanak S, Pu SF, Liang J, Dang C, Iglesias BD, Harvey B, Zhu B, McMonagle SK (2009) Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 256:89-103
17. Norager S, Jensen KF, Bjornberg O, Larsen S (2002) E. coli dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenase. Structure 10:1211-1223
18. Rozman B (1998) Clinical experience with leflunomide in rheumatoid arthritis. J Rheumatol Suppl 53:27-31
19. Shannon PVR, Eichholtz T, Linstead D, Masdin P, Skinner R (1999) Condensed heterocyclic compounds as anti-inflammatory and immunomodulatory agents. International patent WO 99/45926, 1999
20. Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ (1997) Inhibition of platelet-derived growth factormediated signal transduction and tumor growth by N-[4- (trifluoromethyl)-phenyl]-5-methylisoxazole-4-carboxamide. Clin Cancer Res 3:1167-1177
21. Vyas VK, Ghate M (2011) Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Min Rev Med Chem 11:1039-1055
22. Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, Woodward K, Bruneau JM, Hambleton P, Spinella-Jaegle S, Morand P, Courtin O, Sautes C, Westwood R, Hercend T, Kuo EA, Ruuth E (1996) Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Transplant Proc 28:3088-3091
23. Wold S, Sjostrom M, Eriksson L (2001) PLS-regression: a basic tool of chemometrics. Chemo Int Lab Sys 58:109-130